Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FKBP1A | P62942 | 4/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | NCOA1 | Q15788 | 1/20 | 0.39 |
| ▸ | NCOA3 | Q9Y6Q9 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | PTGIR | P43119 | 1/20 | 0.39 |
| ▸ | HCRTR1 | O43613 | 2/20 | 0.38 |
| ▸ | HCRTR2 | O43614 | 2/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
| ▸ | FKBP4 | Q02790 | 1/20 | 0.38 |
| ▸ | FKBP5 | Q13451 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 2/20 | 0.38 |
| ▸ | USP2 | O75604 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL493162 | 0.93 | POLB (0.39) | FKBP1AKMT2AHCRTR1HCRTR2FKBP4 | |
| SCHEMBL493363 | 0.93 | NPC1 (0.40) | FKBP1AHPGDKMT2ANCOA1NCOA3 | |
| SCHEMBL492503 | 0.93 | FKBP1A (0.41) | FKBP1AHPGDKMT2ANCOA1NCOA3 | |
| SCHEMBL492877 | 0.91 | RAB9A (0.47) | FKBP1ARAB9APTGIR | |
| SCHEMBL492898 | 0.90 | FKBP1A (0.42) | FKBP1AHPGDKMT2ANCOA1NCOA3 | |
| SCHEMBL492667 | 0.89 | PTGIR (0.39) | FKBP1AKMT2ARAB9APTGIRHCRTR1 | |
| SCHEMBL492833 | 0.89 | KMT2A (0.39) | FKBP1AHPGDKMT2ANCOA1NCOA3 | |
| SCHEMBL492903 | 0.88 | POLB (0.43) | FKBP1ANCOA1NCOA3TDP1FKBP4 | |
| SCHEMBL493197 | 0.88 | RAB9A (0.39) | HPGDRAB9APTGIRGAAALDH1A1 | |
| SCHEMBL492825 | 0.87 | HTR7 (0.41) | KMT2ARAB9APTGIRHCRTR1HCRTR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8106055-B2 | Substituted amide compounds | GRUENENTHAL GMBH (DE) | 2012-01-31 | — | — | US | claimed |
| US-20080306084-A1 | Substituted Amide Compounds | GRUENENTHAL GMBH (DE) | 2008-12-11 | — | — | US | claimed |
| US-8106055-B2 | Substituted amide compounds | GRUENENTHAL GMBH (DE) | 2012-01-31 | — | — | US | disclosed |
| US-20080306084-A1 | Substituted Amide Compounds | GRUENENTHAL GMBH (DE) | 2008-12-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080306084-A1 | Substituted Amide Compounds | OPRK1, NAA50, ACMSD | FKBP1A 835/4885HPGD 213/4885KMT2A 1749/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.